Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2001

Filing Date
Filed March 29, 2002
Period End
December 31, 2001
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed March 29, 2002. Cited figures are marked; the original filing is the authoritative source.

Schering-Plough Corporation reported net sales of $9,802 milliona for 2001, essentially flat versus $9,815 million in 2000, with volume declines of 2 percent and unfavorable foreign exchange of 2 percent offset by price increases of 4 percent.

Net income fell 20 percent to $1,943 millionb, or $1.32 diluted earnings per share, after a one-time $500 million provision for a consent decree payment tied to FDA good manufacturing practice issues at its New Jersey and Puerto Rico plants. Excluding that provision, net income was $2.3 billion and diluted EPS was $1.58, down 4 percent. Cash provided by operating activities was $2,512 million.

The filing's central investor concern is CLARITIN, which accounted for 28 percent of 2001 worldwide sales ($2.7 billionc in U.S. sales). The company faces patent litigation against 15 generic manufacturers, with generic loratadine possibly entering the market as early as December 20, 2002, and it has filed sNDAs to switch CLARITIN to over-the-counter status with a targeted FDA action date of November 28, 2002. Management states that either generic or OTC entry would likely cause a rapid, sharp and material adverse effect on results of operations.

Other pressures include a negotiated FDA consent decree, a grand jury investigation into managed care transactions, numerous average wholesale price lawsuits, and an IRS assertion of about $195 milliond in additional tax. Growth drivers in 2001 included the INTRON franchise (up 6 percent to $1.4 billion), anti-infectives and anticancer products (up 13 percent), NASONEX (up 26 percent) and REMICADE and TEMODAR.

Cardiovascular sales fell 17 percent, reflecting generic competition for K-DUR and IMDUR. Research and development spending was $1,312 million, about 13 percent of net sales.

Key Highlights

  1. Net sales of $9.80 billion were essentially flat versus $9.82 billion in 2000, with price increases of 4 percent offset by volume declines of 2 percent and unfavorable foreign exchange of 2 percent.
  2. Net income declined 20 percent to $1.94 billion, or $1.32 diluted EPS, including a one-time $500 million provision for an FDA consent decree payment; excluding it, diluted EPS was $1.58, down 4 percent.
  3. CLARITIN accounted for 28 percent of 2001 consolidated worldwide sales, with U.S. CLARITIN sales of $2.7 billion, making it a major concentration risk.
  4. Compound patent for loratadine expires June 19, 2002, with U.S. market exclusivity extended to December 19, 2002; generic loratadine could enter as early as December 20, 2002 if the company does not prevail in 15 patent suits.
  5. Sun-setting OTC switch applications for CLARITIN have a standard FDA review targeted for November 28, 2002; management expects generic or OTC entry to have a rapid, sharp and material adverse effect on results.
  6. INTRON franchise sales rose 6 percent to $1.4 billion and NASONEX rose 26 percent to $524 million, while cardiovascular sales fell 17 percent on generic competition.
  7. Cash provided by operating activities was $2.51 billion, and dividends paid were $911 million, with the $1.5 billion share repurchase program suspended in early 2001.

Frequently Asked Questions

  1. How significant is CLARITIN to Schering-Plough's business?

    CLARITIN sales in the United States, in all formulations, accounted for 28 percent of consolidated worldwide sales in 2001 and a larger percentage of consolidated earnings. Worldwide CLARITIN brand sales totaled $3.2 billion in 2001.

  2. What is the timing risk from generic loratadine and OTC CLARITIN?

    The loratadine compound patent expires June 19, 2002, with U.S. market exclusivity extended to December 19, 2002. If the company does not prevail in its patent suits against 15 manufacturers, generic loratadine could enter the market as early as December 20, 2002. The FDA has accepted sNDAs to switch CLARITIN to OTC status, with a targeted action date of November 28, 2002.

  3. What caused the decline in 2001 net income?

    Net income fell 20 percent to $1,943 million, largely due to a one-time $500 million provision for a payment under a consent decree being negotiated with the FDA over good manufacturing practice compliance at New Jersey and Puerto Rico facilities. Excluding this provision, net income was $2.3 billion, down 4 percent.

  4. What legal and regulatory matters could affect future results?

    The filing describes a grand jury investigation into managed care transactions and potential anti-kickback and Medicaid rebate issues, multiple average wholesale price lawsuits brought by states and private plaintiffs, an FTC administrative proceeding over K-DUR patent settlements, and an IRS assertion of approximately $195 million in additional tax for 1990 through 1992, which the company disputes.

  5. Which products drove growth and which declined in 2001?

    Anti-infective and anticancer sales rose 13 percent to $2,273 million, led by the INTRON franchise and REMICADE, and NASONEX rose 26 percent to $524 million. Cardiovascular sales fell 17 percent to $623 million due to generic competition for K-DUR and IMDUR, and dermatological sales fell 13 percent, mainly from LOTRISONE.